New Two-Pronged cell therapy tested for tough cancers
NCT ID NCT06295549
Summary
This early-stage study tested a new type of cell therapy called LUCAR-G39P in adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses the patient's own modified immune cells to target two markers on the cancer cells. The main goals were to check the treatment's safety, see how it behaves in the body, and find the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Beijing Gobroad Hosptial
Beijing, 102206, China
-
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.